Archer Materials has reported that initial data from first-stage testing of its blood potassium graphene Biochip project have shown the technology suitable for silicon for point-of-care and at-home diagnostic applications. Archer expects the findings to de-risk its supply chain, reduce unit costs, and accelerate the pathway towards manufacture and commercialization.
The company now plans to finalize a working prototype and progress toward clinical trials in the new year as it moves towards project validation and commercial readiness.
Archer Materials has reported that initial data from first-stage testing of its blood potassium graphene Biochip project have shown the technology suitable for silicon for point-of-care and at-home diagnostic applications. Archer expects the findings to de-risk its supply chain, reduce unit costs, and accelerate the pathway towards manufacture and commercialization.The company now plans to finalize a working prototype and progress toward clinical trials in the new year as it moves towards project validation and commercial readiness.
Read More Graphene-Info – Graphene industry portal











